



March 24, 2023

Mah Sing Healthcare Sdn Bhd
Ivan Tan Chee Wei
Senior QA Manager
Lot 6478, Lorong Sungai Puloh/KU6,
Kawasan Industri Sungai Puloh,
Klang, Selangor 42100
Malaysia

Re: K230002

Trade/Device Name: Nitrile Powder Free Black Patient Examination Gloves, Non-sterile, Tested for
Use with Chemotherapy Drugs

Regulation Number: 21 CFR 880.6250

Regulation Name: Non-Powdered Patient Examination Glove

Regulatory Class: Class I, reserved

Product Code: LZA, LZC, OPJ

Dated: January 3, 2023

Received: January 3, 2023

Dear Ivan Tan Chee Wei:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,


Allan Guan -S

For Bifeng Qian, M.D., Ph.D.
Assistant Director
DHT4B: Division of Infection Control
and Plastic Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2023
See PRA Statement below.

Indications for Use

510(k) Number (if known)
K230002

Device Name
Nitrile Powder Free Black Patient Examination Gloves, Non-Sterile, Tested For Use With Chemotherapy Drugs

Indications for Use (Describe)

A patient examination glove is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.

These gloves were tested for use with Chemotherapy Drugs as per ASTM D6978-05 (2019), Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs:

Test Chemotherapy Drugs are as follows:

Test Chemotherapy Drugs Concentration	Minimum Breakthrough Detection Time in minutes
*Carmustine 3.3mg/ml	32.2
Cisplatin 1mg/ml	>240
Cyclophosphamide 20mg/ml	>240
Dacarbazine 10mg/ml	>240
Doxorubicin, HCl 2mg/ml	>240
Etoposide 20mg/ml	>240
Fluorouracil 50mg/ml	>240
Methotrexate 25mg/ml	>240
Mitomycin 0.5mg/ml	>240
Oxaliplatin 5mg/ml	>240
Paclitaxel 6mg/ml	>240
*Thiotepa 10mg/ml	37.4
Vincristine 1mg/ml	>240

Warning: Do not use with Carmustine and Thiotepa.

Please note that the following drugs have low permeation times:

- (1)Carmustine – 32.2 minutes
- (2)Thiotepa – 37.4 minutes

Type of Use (Select one or both, as applicable)

- Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

Premarket Notification [510(k)] No: K230002

510 (K) SUMMARY

1.0 Device Name Nitrile Powder Free Black Patient Examination Gloves, Non-Sterile,
Tested For Use With Chemotherapy Drugs.

**2.0 Submitter name /
Contact details** Mah Sing Healthcare Sdn. Bhd
Lot 6478, Lorong Sungai Puloh/KU6,
Kawasan Industri Sungai Puloh,
Klang, Selangor 42100
MALAYSIA

Contact Person Details:
Ivan Tan Chee Wei (Mr.)
E-mail: ivan.tan@mshealthcare.com
Tel: +60-3-3396 2288, Extn: 2213
Fax: +60-3-3396 2299

**3.0 Summary
Preparation Date** February 20, 2023

**4.0 Device Name &
Classification** Trade Name: Nitrile Powder Free Black Patient Examination Gloves
Non-sterile, Tested for use with Chemotherapy Drugs

Common Name: Nitrile Powder Free Patient Examination Glove

Classification Name: Patient Examination Gloves Specialty
Polymer Patient Examination Gloves

Device Classification: I

Regulation Number: 21 CFR 880.6250

Panel: General Hospital

Product Code: LZA, LZC, OPJ

**5.0 Identification of
The Legally Marketed
Device** Predicate Device Name: Nitrile Powder Free Blue Patient Examination
Gloves, Non-Sterile, Tested For Use With
Chemotherapy Drugs

Predicate 510(K) Number: K214110

Manufacture's Name: Mah Sing Healthcare Sdn. Bhd.

6.0 Description of Device

Nitrile Powder Free Black Patient Examination Gloves Non-sterile, Tested For Use With Chemotherapy Drugs meets all the requirements of ASTM standards D6319-19, D6978-05 (2019) and FDA 21 CFR 880.6250.

The gloves are made from acrylonitrile-butadiene copolymer dispersion. Inner surface of gloves undergoes surface treatment process to produce a smooth surface that assists the user in donning the gloves without using any lubricant such as powder on the glove surface. These gloves are black in color and are powder free. The gloves are ambidextrous i.e., can be worn on right hand or left hand, single use disposable devices that come in five sizes (XS, S, M, L and XL). The physical properties of glove, i.e., tensile strength meet ASTM D 6319-19.

7.0 Indications for Use

A patient examination glove is a disposable device intended for medical purpose that is worn on the examiner’s hand or finger to prevent contamination between patient and examiner. These gloves were tested for use with Chemotherapy Drugs as per ASTM D6978-05 (2019), Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs:

Test Chemotherapy Drugs are as follows:

Test Chemotherapy Drugs	Concentration	Minimum Breakthrough Detection Time in minutes
*Carmustine	3.3mg/ml	32.2
Cisplatin	1 mg/ml	>240
Cyclophosphamide	20 mg/ml	>240
Dacarbazine	10 mg/ml	>240
Doxorubicin, HCl	2 mg/ml	>240
Etoposide	20 mg/ml	>240
Fluorouracil	50 mg/ml	>240
Methotrexate	25 mg/ml	>240
Mitomycin	0.5 mg/ml	>240
Oxaliplatin	5 mg/ml	>240
Paclitaxel	6 mg/ml	>240
*Thiotepa	10 mg/ml	37.4
Vincristine	1 mg/ml	>240

*Warning: Do not use with Carmustine and Thiotepa

Note:

Please note that the following drugs have low permeation times:

- (1) Carmustine – 32.2 minutes
- (2) Thiotepa – 37.4 minutes.

8.0 Summary of the Technological Characteristic of The Device

Nitrile Powder Free Black Patient Examination Gloves Non-sterile, Tested For Use with Chemotherapy Drugs meets all the requirements of ASTM standards D6319-19, D6978-05 (2019) and FDA 21 CFR 880.6250

Table 1

Characteristics and Parameters	Standard	Proposed Device	Predicate device	Comparison Analysis
510(k) Number	-	K230002	K214110	-
Manufacturer	-	Mah Sing Healthcare Sdn. Bhd.	Mah Sing Healthcare Sdn. Bhd.	Same
Name of device		Nitrile Powder Free Black Patient Examination Gloves, Non-Sterile, Tested for use with chemotherapy drugs and	Nitrile Powder Free Blue Patient Examination Gloves, Non-Sterile, Tested for use with chemotherapy drugs	Similar
Device Classification Name/Regulation Number	Patient Examination Glove, 21 CFR Part 880.6250	Patient Examination Glove, 21 CFR Part 880.6250	Patient Examination Glove, 21 CFR Part 880.6250	Same
Product Code	-	LZA, LZC, OPJ	LZA, LZC	Same
Classification	-	Class 1	Class 1	Same
Raw Rubber Material	ASTM D 6319-19	Nitrile	Nitrile	Same
Color	-	Black	Blue	Different

Characteristics and Parameters	Standard	Proposed Device (K230002)	Predicate device (K214110)	Comparison Analysis
Chemotherapy Drug Permeation Test	ASTM D6897-05			
Test Chemotherapy Drugs	Concentration	Minimum Breakthrough Detection Time (min)		
*Carmustine	3.3mg/ml	32.2	24.8	Similar Below 240 minutes permeation times
Cisplatin	1 mg/ml	>240	>240	Similar
Cyclophosphamide	20 mg/ml	>240	>240	Similar
Dacarbazine	10 mg/ml	>240	>240	Similar
Doxorubicin, HCl	2 mg/ml	>240	>240	Similar
Etoposide	20 mg/ml	>240	>240	Similar
Fluorouracil	50 mg/ml	>240	>240	Similar
Methotrexate	25 mg/ml	>240	Not tested	Optional, Subject device perform additional Chemotherapy drug test
Mitomycin	0.5 mg/ml	>240	Not tested	Optional, Subject device perform additional Chemotherapy drug test
Oxaliplatin	5 mg/ml	>240	Not tested	Optional, Subject device perform additional Chemotherapy drug test
Paclitaxel	6 mg/ml	>240	>240	Similar
*Thiotepa	10 mg/ml	37.4	38.4	Similar Below 240 minutes permeation times
Vincristine	1 mg/ml	>240	>240	Similar

Characteristics and Parameters	Standard	Proposed Device (K230002)	Predicate device (K214110)	Comparison Analysis
Length XS: Min.220mm S: Min.220mm M: Min.230mm L: Min.230mm XL: Min.230mm	ASTM D 6319-19	XS: 244 - 247mm S: 243 - 248mm M: 243 - 252mm L: 243 - 249mm XL: 243 - 249mm	245 - 255mm	Similar
Width XS:60mm - 80mm S: 70mm - 90mm M: 85mm - 105mm L: 100mm - 120mm XL:110mm - 130mm	ASTM D 6319-19	XS: 76 - 78mm S: 81 - 88mm M: 95 - 99mm L: 102 - 111mm XL: 111 - 119mm	S: 83 - 85mm M: 93 - 96mm L: 105 - 109mm XL: 116 - 118mm	Similar
Palm Thickness (Minimum 0.05mm)	ASTM D 6319-19	0.06 - 0.07mm	0.06 - 0.07mm	Similar
Finger Thickness (Minimum 0.05mm)	ASTM D 6319-19	0.07 - 0.08mm	0.08 - 0.11mm	Similar
Tensile Strength (Before aging) Minimum 14 MPa	ASTM D 6319-19	Average: 25.31MPa	Average: 21.96MPa	Similar
Tensile Strength (After accelerated aging) Minimum 14 MPa	ASTM D 6319-19	Average: 26.38MPa	Average: 28.30MPa	Similar
Ultimate Elongation (before aging) Minimum 500%	ASTM D 6319-19	Average: 533%	Average: 537%	Similar
Ultimate Elongation (after accelerated aging) Minimum 400%	ASTM D 6319-19	Average: 455%	Average: 449%	Similar
Freedom of Holes Meet AQL 2.5 at G1	ASTM D 5151-19	Meet AQL 1.5 with G1	Meet AQL 1.5 with G1	Same
Residual powder test (Less than 2mg/glove)	ASTM D 6124-06	Average powder residue for each size. XS: 0.23mg/glove S: 0.20mg/glove M: 0.25mg/glove L: 0.25mg/glove XL: 0.30mg/glove	Average powder residue for each size. S: 0.32mg/glove M: 0.28mg/glove L: 0.32mg/glove XL: 0.30mg/glove	Similar
Animal Irritation Test	ISO 10993-10 Biological evaluation of medical devices - Part 10: Tests for irritation and skin Sensitization	Passed. Under the conditions of study, not an irritant	Passed. Under the conditions of study, not an irritant	Same
Dermal Sensitization	ISO 10993-10 Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization	Passed. Under the conditions of study, not a sensitizer	Passed. Under the conditions of study, not a sensitizer	Same
Acute Systemic Toxicity	ISO 10993-11 Biological evaluation of medical devices - Part 11: Tests for systemic toxicity	Not induce acute systemic toxicity	Not induce acute systemic toxicity	Same

Characteristics and Parameters	Standard	Proposed Device (K230002)	Predicate device (K214110)	Comparison Analysis
Indication for use	-	Nitrile Powder Free Black Patient Examination Gloves, Non-Sterile, Tested for Use with Chemotherapy Drugs is a patient examination glove is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. These gloves were tested for use with Chemotherapy Drugs as per ASTM D6978-05 (2019), Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.	Nitrile Powder Free Blue Patient Examination Gloves, Non-Sterile, Tested for Use with Chemotherapy Drugs is a patient examination glove is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. These gloves were tested for use with Chemotherapy Drugs as per ASTM D6978-05 (2019), Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.	Same

9.0 Summary of Non-Clinical Testing

Table 2 -Performance Testing

Non-Clinical Testing					
Test Method	Purpose	Acceptance Criteria		Result	
ASTM D6124-06 (Reapproved 2017) Standard Test Method for Residual Powder on Medical Gloves.	To determine the residual powder in the gloves	Less than 2mg / glove		Size XS Size S Size M Size L Size XL	0.23mg/glove 0.20mg/glove 0.25mg/glove 0.25mg/glove 0.30mg/glove
ASTM D5151-19 Standard Test Method for Detection of Holes in Medical Gloves.	To determine the holes in the gloves	Inspection level, G-I AQL 2.5 (In accordance with ASTM D6319-19)		Passed G-I, AQL 1.5	
ASTM D6319-19 Standard Specification for Nitrile Examination Gloves for Medical Application.	To determine the length of the gloves	Size XS Size S Size M Size L Size XL	220mm, min 220mm, min 230mm, min 230mm, min 230mm, min	Size XS Size S Size M Size L Size XL	244 - 247mm 243 - 248mm 243 - 252mm 243 - 249mm 243 - 249mm
ASTM D6319-19 Standard Specification for Nitrile Examination Gloves for Medical Application.	To determine the width of the gloves	Size XS Size S Size M Size L Size XL	70 ± 10mm 80 ± 10mm 95 ± 10mm 110 ± 10mm 120 ± 10mm	Size XS Size S Size M Size L Size XL	76 - 78mm 81 - 88mm 95 - 99mm 102 - 111mm 111 - 119mm

Non-Clinical Testing (Cont'd)					
Test Method	Purpose	Acceptance Criteria		Result	
ASTM D6319-19 Standard Specification for Nitrile Examination Gloves for Medical Application.	To determine the thickness of the gloves	Measured in single wall at approximate center of palm area			
		Palm	0.05mm, min	Size XS Size S Size M Size L Size XL	0.06 - 0.07mm 0.06 - 0.07mm 0.06 - 0.07mm 0.06 - 0.07mm 0.06 - 0.07mm
		Measured in single wall at 13±3mm from the tip of middle finger			
		Finger	0.05mm, min	Size XS Size S Size M Size L Size XL	0.07 - 0.08mm 0.07 - 0.08mm 0.07 - 0.08mm 0.07 - 0.08mm 0.07 - 0.08mm
ASTM D6319-19 Standard Specification for Nitrile Examination Gloves for Medical Application.	To determine the physical properties- Tensile strength	Before Ageing Tensile Strength 14Mpa, min for all sizes		Size XS Size S Size M Size L Size XL	23.79 MPa, average 24.89 MPa, average 25.39 MPa, average 26.44 MPa, average 26.05 MPa, average
		After Ageing Tensile Strength 14Mpa, min for all sizes		Size XS Size S Size M Size L Size XL	27.52 MPa, average 26.28 MPa, average 25.93 MPa, average 26.21 MPa, average 25.98 MPa, average
	To determine the physical properties- Ultimate Elongation	Before Ageing Ultimate Elongation 500%, min for all sizes		Size XS Size S Size M Size L Size XL	539%, average 533%, average 527%, average 538%, average 526%, average
		After Ageing Ultimate Elongation 400%, min for all sizes		Size XS Size S Size M Size L Size XL	435%, average 453%, average 460%, average 455%, average 470%, average

Non-Clinical Testing (Cont'd)			
Test Method	Purpose	Acceptance Criteria	Result
ASTM D6897-05 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs	To provide a uniform procedure for assessing the resistance of medical glove materials to permeation by chemotherapy drugs, and to establish a consistent reporting of the test data.	>240 minutes	*Carmustine 3.3mg/ml = 32.2 Cisplatin 1 mg/ml = >240 Cyclophosphamide 20 mg/ml = >240 Dacarbazine 10 mg/ml = >240 Doxorubicin, HCl 2 mg/ml = >240 Etoposide 20 mg/ml = >240 Fluorouracil 50 mg/ml = >240 Methotrexate 25 mg/ml = >240 Mitomycin 0.5 mg/ml = >240 Oxaliplatin 5 mg/ml = >240 Paclitaxel 6 mg/ml = >240 *Thiotepa 10 mg/ml = 37.4 Vincristine 1 mg/ml = >240

Biocompatibility Testing			
Test Method	Purpose	Acceptance Criteria	Result
ISO 10993-10 Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization (Animal Irritation Test)	To determine the potential of the material under test to produce dermal irritation in Rabbits	Under the condition of study not an irritant.	There was no observable irreversible alteration on the skin at the sites of contact with the test material. The Primary Irritation Index (PII) was "0". The test material was not irritant and the Primary Irritation Response Category is therefore "negligible", thereof met the requirement.
ISO 10993-10 Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization (Dermal Sensitization Assay Test)	To determine the skin sensitization potential of the material both in terms of induction and elicitation in Guinea pig	Under the condition of the study not a sensitizer.	There was no sensitization induced by the application of the test material on the albino guinea pigs under the condition of this test, thereof met the requirement.
ISO 10993-11 Biological evaluation of medical devices - Part 11: Tests for systemic toxicity (Acute Systemic Toxicity)	To provide information on health hazards likely to arise from a short-term exposure to the extracts of test material by intravenous and intraperitoneal injection in mice	Not induce acute systemic toxicity	Under the condition of this study, the single dose acute systemic toxicity of extracts from test material using both normal saline and sesame oil, did not demonstrate any adverse toxic reaction, thereof met the requirement.

Non-clinical tests were carried out to demonstrate product performance conformity with the standards referenced.

The following bench tests were performed:

Non-clinical tests

- Residual Powder Content
- Physical Properties
- Physical Dimension
- Freedom from Holes
- Chemotherapy Drug Permeation Test

Biocompatibility Testing

- Animal Irritation Test
- Dermal Sensitization Assay
- Acute Systemic Toxicity

The results from these performance evaluations demonstrated that the Nitrile Powder Free Black Patient Examination Gloves, Non-Sterile, Tested for Use With Chemotherapy Drugs met the acceptance criteria defined in standards referenced.

10.0 Summary of Clinical Testing

Clinical Testing is not needed for this device.

11.0 Conclusion

The conclusion drawn from the non-clinical test demonstrate that the subject device is as safe, as effective, and performs as well as or better than the legally marketed predicate device.
